Navigation Links
VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference
Date:2/3/2009

ROCHESTER, N.Y., Feb. 3 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that Mr. Jeff Markin, the company's chief executive officer, will be presenting a corporate overview at the upcoming 11th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Mr. Markin's presentation will be on Tuesday, February 10, 2009 at 3:45pm EST.

A live webcast of the presentation will be available for 30 days in the Investor Relations section of the company's website, www.virtualscopics.com.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards in 2008 and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.


    CONTACT:  Company Contact:
              Molly Henderson
              Chief Business and Financial Officer
              500 Linden Oaks
              Rochester, New York 14625
              (585)249.6231

'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Backlog Rises to a Record $27 Million
2. VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit
3. VirtualScopics to Present at Two Upcoming Investor Conferences
4. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
5. VirtualScopics Reports Second Quarter 2008 Results
6. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
7. VirtualScopics Backlog Exceeds a Record $20 Million
8. VirtualScopics Announces $4.35 Million Private Placement
9. Illinois Department of Veterans Affairs Presents $97,500 Veterans Cash Grant to Alexian Brothers Hospital Network
10. ISTA Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
11. Womans Day Presents the Sixth Annual Red Dress Awards Honoring Women Making Strides in the Fight Against Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... without a referral to new patients from Burnaby, BC. Patients in need of ... mouth reconstruction services, can see the esteemed team at Wall Centre Dental. Drs. ...
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... continues developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices ... the first ANSI-approved GMP standard for dietary supplements this spring, is hiring ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... March 29, 2017 ... ... and hassles associated with wearing oral braces. "The rubber bands used in conjunction ... he said, "so I decided to design a way to prevent this problem." ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical ... ended December 31, 2016 after market close on ... released later than the previous fiscal year,s results ... and balances of Apicore from the acquisition date ... date meets TSX Venture Exchange listed company requirements. ...
(Date:3/28/2017)... 28, 2017 "Chemotherapy Induced Neutropenia (CIN) – Market Insights, ... and global market trends of the Chemotherapy Induced Neutropenia for the ... Europe ( France , ... , UK) and Japan , as well ... of the world (RoW). The Report covers the therapeutics ...
(Date:3/28/2017)... March 28, 2017  "US Cancer Generics Market ... various indicators and trend analysis related to the ... mainstream pharmaceutical market in US. The report analyzes ... growth on cancer generics drugs in recent years. ... of billions of dollars for various stake holders ...
Breaking Medicine Technology: